Layoffs before MNK155??

[Anonymous]

Obviously this launch is a failure and they don't need the size sales force they have. BUT they recognize it is their fault for the launch screw up and are giving us more time to get Xartemis moving. With MNK 155 around the corner, do you think they will lay off before or hold out?

 

[Anonymous]

We are on the bubble...boss is giving signals.

 

[Anonymous]

Do tell! What signals?

 

[Anonymous]

We are on the bubble...boss is giving signals.

liar.

 

[Anonymous]

liar.

Apparently s/he was telling the truth. You were just too blind too see it coming.

 

[Anonymous]

If you didn't see this coming, you are blind. My boss played nicely nicey and didn't give any clues.

 

[Anonymous]

If you didn't see this coming, you are blind. My boss played nicely nicey and didn't give any clues.

they just killed this drug. unbelievable.

 

[Anonymous]

XXR is dead. 155 will have no reps to sell in the field by launch. What a shitstorm.

 

[Anonymous]

The main questions are:
1. Will MNK155 have any labeling different from XXR? (tamper resistant or non-preferential)
2. Will it be a C-II or C-III? (call it in)
3. Will there be a different approach for stocking, Managed Care?
4. Will the clinical studies cover more than a single specialty? Any for Orthos? or other high potential specialties like ENTs, oral surgeons, ER doctors, general surgeons?
5. Will it have some clinicals for higher dosing. i.e. Where does a Dr go if 2 XXR twice a day is not enough?
6. Will the reps have any studies to discuss?

Let's hope we can learn from XXR for MNK155.

 

[Anonymous]

Right...With this management group? Good luck with that.